Karachi: GlaxoSmithKline Pakistan Limited has submitted its Shariah disclosure report for the half-year ending June 30, 2026. This compliance follows PSX Notice No PSX/Gen-1073 dated September 11, 2026, which continues from an earlier notice, PSX/N-435 dated April 17, 2026. The submission adheres to Clause 5.6.9A.2 and Clause 5A.13(e)(ii) of the PSX Regulations, alongside Clause VII of Part I of Schedule IV of the Companies Act, 2017.

According to the report, GlaxoSmithKline maintains Shariah-compliant bank balances amounting to 2,849,000 rupees, a marginal increase from 2,820,000 rupees recorded as of December 31, 2025. Revenue earned from the Shariah-compliant business segment reached 31,519.29 million rupees for the half-year ending June 30, 2026, up from 30,300.81 million rupees in the same period of 2025. This represents a very large or significant move of 4.02%.

The company reported a notable exchange gain of 22,489,000 rupees compared to a loss of 155,293,000 rupees in the previous year. Income from the gain on disposal of operating assets was 80,688,000 rupees, and scrap sales amounted to 60,533,000 rupees. Promotional allowances decreased to 163,118,000 rupees from 395,926,000 rupees, while the service fee saw a decline to 4,200,000 rupees from 7,986,000 rupees.

According to information available from the Pakistan Stock Exchange (PSX), the company also reported other income, including 44,634,000 rupees under 'Others' and income from conventional savings accounts at 359,963,000 rupees, up from 204,578,000 rupees. These figures highlight the company's financial positioning and adherence to Shariah compliance requirements as set by regulatory authorities.

The disclosure ensures compliance with PSX Regulations and the Companies Act, 2017, reflecting GlaxoSmithKline Pakistan Limited's commitment to transparency and regulatory adherence.